Gokce Naz Kucukbas
Research Subjects
Gokce Naz Kucukbas has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Arzu Yavuz
Department of Obstetrics and Gynecology, Kocaeli City Hospital, University of Health Sciences
2 shared publications- Dilek Sahin
Perinatology Department Ankara Bilkent City Hospital Ankara Turkey
2 shared publications Hanım Güler Şahin
Obstetrics and Gynecology, Van Yüzüncü Yıl University, Van, TUR
2 shared publicationsA. Seval Ozgu-Erdinc
Perinatology Division, Obstetrics and Gynecology Department, Izmir City Hospital, University of Health Sciences
1 shared publicationA. U. Komuroglu
Van Yuzuncu Yil Univ, Hlth Serv Vocat Sch Higher Educ, Van, Turkiye
1 shared publicationA. Yavuz
Univ Hlth Sci, Derince Training & Res Hosp, Dept Obstet & Gynecol, Kocaeli, Turkiye
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1935421
Efficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis
Background: Respiratory syncytial virus (RSV) is the leading cause of infant lower respiratory tract infection (LRTI) and hospitalisation worldwide. Maternal RSV prefusion F (RSVpreF) vaccination protects infants through transplacental antibody transfer. We aimed to synthesise the efficacy, real-world effectiveness, and safety of maternal RSV vaccination for preventing infant LRTI, integrating randomised and observational evidence. Methods: We searched PubMed, Embase, Scopus, and Cochrane CENTRAL (to June 2026) for randomised controlled trials (RCTs) and observational studies of maternal RSV vaccination reporting infant LRTI, hospitalisation, or maternal–infant safety. A single reviewer, with large language model-assisted verification, screened records, extracted data, and assessed risk of bias (RoB 2; Newcastle–Ottawa Scale). Randomised and observational evidence were pooled separately using random-effects models; overlapping populations were resolved based on study periods and named participating sites. Certainty was rated with GRADE (PROSPERO CRD420261400053). Results: Twenty-four studies (9 RCTs enrolling approximately 18,600 pregnant women, 15 observational) were included; all 15 observational studies evaluated the licensed Pfizer vaccine (Abrysvo). Pooled vaccine effectiveness against infant RSV-associated hospitalisation was 79.7% (95% CI 73.9–84.2) within 3 months and 68.1% (57.1–76.3) through 6 months. Randomised efficacy against severe RSV-LRTI was 70% for the licensed Pfizer vaccine, closely concordant with the real-world effectiveness; efficacy against medically attended RSV-LRTI was 51.5% (36.3–63.1). Preterm birth was modestly increased in the randomised trials (Mantel–Haenszel RR 1.17, 95% CI 1.03–1.32), but the signal was not robust: it became non-significant after excluding the GSK trial (GRACE; 1.10, 0.95–1.27), and for the licensed Pfizer vaccine, the increase was small and not robustly significant (pivotal MATISSE trial 1.20, 0.98–1.46; three-trial Pfizer pool 1.21, 1.00–1.46), while observational data showed a biologically implausible protective association (0.90, 0.82–0.99), consistent with healthy vaccinee confounding. No other maternal or neonatal safety signal was identified. Certainty of evidence was moderate for effectiveness and efficacy. Conclusion: Maternal RSVpreF vaccination confers substantial, generalisable protection against infant RSV disease, with randomised and real-world evidence in close agreement. For the licensed Pfizer vaccine administered within its approved 32–36-week window, no robustly significant increase in preterm birth is established, supporting its continued programmatic use alongside ongoing post-marketing surveillance. Systematic review registration: Unique Identifier: CRD420261400053 https://www.crd.york.ac.uk/PROSPERO/view/CRD420261400053
- 18 September 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1935421
Open AccessEfficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis
Background: Respiratory syncytial virus (RSV) is the leading cause of infant lower respiratory tract infection (LRTI) and hospitalisation worldwide. Maternal RSV prefusion F (RSVpreF) vaccination protects infants through transplacental antibody transfer. We aimed to synthesise the efficacy, real-world effectiveness, and safety of maternal RSV vaccination for preventing infant LRTI, integrating randomised and observational evidence. Methods: We searched PubMed, Embase, Scopus, and Cochrane CENTRAL (to June 2026) for randomised controlled trials (RCTs) and observational studies of maternal RSV vaccination reporting infant LRTI, hospitalisation, or maternal–infant safety. A single reviewer, with large language model-assisted verification, screened records, extracted data, and assessed risk of bias (RoB 2; Newcastle–Ottawa Scale). Randomised and observational evidence were pooled separately using random-effects models; overlapping populations were resolved based on study periods and named participating sites. Certainty was rated with GRADE (PROSPERO CRD420261400053). Results: Twenty-four studies (9 RCTs enrolling approximately 18,600 pregnant women, 15 observational) were included; all 15 observational studies evaluated the licensed Pfizer vaccine (Abrysvo). Pooled vaccine effectiveness against infant RSV-associated hospitalisation was 79.7% (95% CI 73.9–84.2) within 3 months and 68.1% (57.1–76.3) through 6 months. Randomised efficacy against severe RSV-LRTI was 70% for the licensed Pfizer vaccine, closely concordant with the real-world effectiveness; efficacy against medically attended RSV-LRTI was 51.5% (36.3–63.1). Preterm birth was modestly increased in the randomised trials (Mantel–Haenszel RR 1.17, 95% CI 1.03–1.32), but the signal was not robust: it became non-significant after excluding the GSK trial (GRACE; 1.10, 0.95–1.27), and for the licensed Pfizer vaccine, the increase was small and not robustly significant (pivotal MATISSE trial 1.20, 0.98–1.46; three-trial Pfizer pool 1.21, 1.00–1.46), while observational data showed a biologically implausible protective association (0.90, 0.82–0.99), consistent with healthy vaccinee confounding. No other maternal or neonatal safety signal was identified. Certainty of evidence was moderate for effectiveness and efficacy. Conclusion: Maternal RSVpreF vaccination confers substantial, generalisable protection against infant RSV disease, with randomised and real-world evidence in close agreement. For the licensed Pfizer vaccine administered within its approved 32–36-week window, no robustly significant increase in preterm birth is established, supporting its continued programmatic use alongside ongoing post-marketing surveillance. Systematic review registration: Unique Identifier: CRD420261400053 https://www.crd.york.ac.uk/PROSPERO/view/CRD420261400053
- Open Access
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1847438
The Turkish validation of the fullPIERS model to predict adverse maternal and fetal outcomes in preeclamptic pregnancies
Introduction: The fullPIERS (The Preeclampsia Integrated Estimate of Risk) model was developed and used in a prospective, multicenter study to identify women with preeclampsia at risk of developing complications within 7 days. This research aimed to elucidate the fullPIERS model and conduct its Turkish validation. Methods: A total of 214 women with singleton pregnancies complicated by preeclampsia at or before 40 weeks of gestation were retrospectively evaluated; 170 met the inclusion criteria and were included in the study. The diagnosis of preeclampsia was established in accordance with the diagnostic criteria outlined in the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin. FullPIERS scores were calculated using the online calculator available on the University of British Columbia Faculty of Medicine website. Results: There were statistically significant differences in gestational age at hospital admission and gestational age at delivery between patients who experienced maternal and/or fetal adverse events and those who did not ( p < 0.05). There was also a significant difference in birth weight in combined maternal–fetal adverse event group and only maternal adverse event group ( p = 0.001 and p < 0.05, respectively). There were differences in systolic blood pressure, creatinine, and AST values between those who experienced adverse events in mother and baby and those who did not (p < 0.001, p < 0.001, and p = 0.011, respectively). There were differences in systolic blood pressure, creatinine, AST, platelet count, proteinuria and oxygen saturation values between those who experienced only maternal adverse events and those who did not (p < 0.05, p < 0.001, p = 0.009, p < 0.05, p < 0.05 and p < 0.016 respectively). There was a significant difference in the fullPIERS score between those who experienced maternal, fetal, or combined maternal–fetal adverse events and those who did not ( p < 0.001, p = 0.002 and p < 0.001, respectively). Discussion: The fullPIERS model captures key pathophysiological features of severe preeclampsia and demonstrates robust risk discrimination in a Turkish cohort in maternal and/or fetal adverse events, supporting its broader application in complication risk-oriented obstetric care.
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1847438
Open AccessThe Turkish validation of the fullPIERS model to predict adverse maternal and fetal outcomes in preeclamptic pregnancies
Introduction: The fullPIERS (The Preeclampsia Integrated Estimate of Risk) model was developed and used in a prospective, multicenter study to identify women with preeclampsia at risk of developing complications within 7 days. This research aimed to elucidate the fullPIERS model and conduct its Turkish validation. Methods: A total of 214 women with singleton pregnancies complicated by preeclampsia at or before 40 weeks of gestation were retrospectively evaluated; 170 met the inclusion criteria and were included in the study. The diagnosis of preeclampsia was established in accordance with the diagnostic criteria outlined in the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin. FullPIERS scores were calculated using the online calculator available on the University of British Columbia Faculty of Medicine website. Results: There were statistically significant differences in gestational age at hospital admission and gestational age at delivery between patients who experienced maternal and/or fetal adverse events and those who did not ( p < 0.05). There was also a significant difference in birth weight in combined maternal–fetal adverse event group and only maternal adverse event group ( p = 0.001 and p < 0.05, respectively). There were differences in systolic blood pressure, creatinine, and AST values between those who experienced adverse events in mother and baby and those who did not (p < 0.001, p < 0.001, and p = 0.011, respectively). There were differences in systolic blood pressure, creatinine, AST, platelet count, proteinuria and oxygen saturation values between those who experienced only maternal adverse events and those who did not (p < 0.05, p < 0.001, p = 0.009, p < 0.05, p < 0.05 and p < 0.016 respectively). There was a significant difference in the fullPIERS score between those who experienced maternal, fetal, or combined maternal–fetal adverse events and those who did not ( p < 0.001, p = 0.002 and p < 0.001, respectively). Discussion: The fullPIERS model captures key pathophysiological features of severe preeclampsia and demonstrates robust risk discrimination in a Turkish cohort in maternal and/or fetal adverse events, supporting its broader application in complication risk-oriented obstetric care.
- Open Access
- 27 April 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 170-171
A CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy
- 27 April 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 170-171
Open AccessA CML Patient with Unintentional Bosutinib Exposure During the First Trimester of Pregnancy
- 1 December 2024
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 22 (4) , 722-728
Determining treatment success in tubal ectopic pregnancies – the predictive value of the delta neutrophil index in single-dose methotrexate therapy
Introduction and aim. This study assessed the significance of the Delta neutrophil index (DNI) in predicting the effectiveness of single-dose methotrexate (MTX) treatment for tubal ectopic pregnancy. Material and methods. In this retrospective study, 214 women diagnosed with tubal ectopic pregnancies and treated with MTX between 2019 and 2022 were included. Group 1 comprised 88 MTX responders, while group 2 consisted of 86 non-re sponders necessitating surgery. HCG and DNI levels were monitored on day 1, 4, and 7 of MTX treatment and compared be tween the groups. Results. Group 1 exhibited significantly lower HCG and DNI levels compared to group 2 on days 1, 4, and 7 (p<0.001). Both HCG and DNI levels on days 1 and 4 of MTX treatment were significant predictors of treatment failure, with the highest AUC observed for DNI was on day 4. In multivariate logistic regression analysis, elevated DNI levels on day 1 of MTX treatment were associated with a 5.8-fold increased risk, and DNI levels on day 4 were associated with a 4.44-fold increased risk of MTX treatment failure. Conclusion. DNI emerges as a valuable marker for predicting the success of single-dose methotrexate treatment in tubal ecto pic pregnancies, demonstrating superior predictive power compared to HCG.
- 1 December 2024
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 22 (4) , 722-728
Determining treatment success in tubal ectopic pregnancies – the predictive value of the delta neutrophil index in single-dose methotrexate therapy
Introduction and aim. This study assessed the significance of the Delta neutrophil index (DNI) in predicting the effectiveness of single-dose methotrexate (MTX) treatment for tubal ectopic pregnancy. Material and methods. In this retrospective study, 214 women diagnosed with tubal ectopic pregnancies and treated with MTX between 2019 and 2022 were included. Group 1 comprised 88 MTX responders, while group 2 consisted of 86 non-re sponders necessitating surgery. HCG and DNI levels were monitored on day 1, 4, and 7 of MTX treatment and compared be tween the groups. Results. Group 1 exhibited significantly lower HCG and DNI levels compared to group 2 on days 1, 4, and 7 (p<0.001). Both HCG and DNI levels on days 1 and 4 of MTX treatment were significant predictors of treatment failure, with the highest AUC observed for DNI was on day 4. In multivariate logistic regression analysis, elevated DNI levels on day 1 of MTX treatment were associated with a 5.8-fold increased risk, and DNI levels on day 4 were associated with a 4.44-fold increased risk of MTX treatment failure. Conclusion. DNI emerges as a valuable marker for predicting the success of single-dose methotrexate treatment in tubal ecto pic pregnancies, demonstrating superior predictive power compared to HCG.
- Open Access
- 27 October 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (5) , 516-523
Systemic immune inflammation indices: novel predictors for preterm premature rupture of membranes and associated complications
Aim: This study aimed to investigate the relationship between systemic immune inflammation (SII) and response indices (SIRI), which are new markers of systemic inflammation derived from immune cells, and preterm premature rupture of membranes (PPROM), as well as adverse pregnancy outcomes. Materials and Methods: The retrospective study included 75 singleton pregnancies complicated with PPROM between 24 and 34 gestational weeks and 75 healthy pregnant women who delivered at term (control group). Inflammation indices were calculated based on neutrophil (N), platelet (P), lymphocyte (L), and monocyte (M) counts as follows: The neutrophil-to-lymphocyte ratio (NLR) = N/L; the platelet-to-lymphocyte ratio (PLR) = P/L; SII = (N×P)/L; and SIRI = (N×M)/L. Results: The median NLR (4.8 vs. 3.5, p
- 27 October 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (5) , 516-523
Open AccessSystemic immune inflammation indices: novel predictors for preterm premature rupture of membranes and associated complications
Aim: This study aimed to investigate the relationship between systemic immune inflammation (SII) and response indices (SIRI), which are new markers of systemic inflammation derived from immune cells, and preterm premature rupture of membranes (PPROM), as well as adverse pregnancy outcomes. Materials and Methods: The retrospective study included 75 singleton pregnancies complicated with PPROM between 24 and 34 gestational weeks and 75 healthy pregnant women who delivered at term (control group). Inflammation indices were calculated based on neutrophil (N), platelet (P), lymphocyte (L), and monocyte (M) counts as follows: The neutrophil-to-lymphocyte ratio (NLR) = N/L; the platelet-to-lymphocyte ratio (PLR) = P/L; SII = (N×P)/L; and SIRI = (N×M)/L. Results: The median NLR (4.8 vs. 3.5, p
- Open Access
- 18 October 2023
- Published by Springer Nature in Cureus
- Vol. 15 (10) , e47287
The Relationship Between Fetal Central Nervous System Malformations and Modified Myocardial Performance Index
Introduction: Fetal ventriculomegaly, the most commonly identified abnormality of the fetal central nervous system (CNS), has been associated with elevated levels of the modified myocardial performance index (mMPI). However, the impact of other CNS pathologies on mMPI has not yet been evaluated. This study aimed to investigate whether there were changes in the myocardial performance index of fetuses with CNS pathologies without congenital heart diseases. Methods: A total of 126 singleton pregnant women were included in this study. Sixty-three fetuses had fetal CNS abnormalities of acrania, anencephaly, encephalocele, Dandy-Walker malformation, hydrocephalus, and meningocele. The control group consisted of 63 healthy and gestational age-matched fetuses. All ultrasonographic examinations were done in the second trimester of gestation. The data related to the characteristics of pregnant women were evaluated, and fetal left ventricular mMPI was obtained by ultrasound scan. Results: The study and the control group participants were not significantly different by means of pregnancy characteristics. The mean mMPI was higher in the fetal CNS malformation group compared to the control groups (0.39±0.02 vs. 0.45±0.04, P<0.001). The mean mMPI value was similar for fetuses with both closed and open calvarium defects of fetal CNS malformation. Conclusion: Fetal CNS anomalies may be associated with prenatal cardiac dysfunction. Moreover, this relationship might be independent of the type of fetal CNS malformation, whether a closed or open calvarium defect.
- 18 October 2023
- Published by Springer Nature in Cureus
- Vol. 15 (10) , e47287
Open AccessThe Relationship Between Fetal Central Nervous System Malformations and Modified Myocardial Performance Index
Introduction: Fetal ventriculomegaly, the most commonly identified abnormality of the fetal central nervous system (CNS), has been associated with elevated levels of the modified myocardial performance index (mMPI). However, the impact of other CNS pathologies on mMPI has not yet been evaluated. This study aimed to investigate whether there were changes in the myocardial performance index of fetuses with CNS pathologies without congenital heart diseases. Methods: A total of 126 singleton pregnant women were included in this study. Sixty-three fetuses had fetal CNS abnormalities of acrania, anencephaly, encephalocele, Dandy-Walker malformation, hydrocephalus, and meningocele. The control group consisted of 63 healthy and gestational age-matched fetuses. All ultrasonographic examinations were done in the second trimester of gestation. The data related to the characteristics of pregnant women were evaluated, and fetal left ventricular mMPI was obtained by ultrasound scan. Results: The study and the control group participants were not significantly different by means of pregnancy characteristics. The mean mMPI was higher in the fetal CNS malformation group compared to the control groups (0.39±0.02 vs. 0.45±0.04, P<0.001). The mean mMPI value was similar for fetuses with both closed and open calvarium defects of fetal CNS malformation. Conclusion: Fetal CNS anomalies may be associated with prenatal cardiac dysfunction. Moreover, this relationship might be independent of the type of fetal CNS malformation, whether a closed or open calvarium defect.
- 1 October 2023
- Vol. 27 (20) , 9902-9907
Maternal serum xenin-25 levels in gestational diabetes mellitus
OBJECTIVE: Xenin-25 is a polypeptide having an insulinotropic effect via increasing the insulin-releasing action of glucose-dependent insulinotropic polypeptide (GIP) and promoting beta cell survival and proliferation. We aimed to assess serum xenin-25 levels in euglycemic pregnancies vs. pregnancies complicated with gestational diabetes mellitus (GDM). PATIENTS AND METHODS: Forty pregnancies complicated with GDM and 40 healthy pregnancies with gestational age between 24 and 28 weeks were included. Following eight hours of fasting, blood samples were drawn from the participants, and subsequently, 75 g of glucose was administered orally. Blood was drawn again 120 minutes after the glucose challenge. Serum xenin-25 levels were detected by ELISA. Statistical analysis was performed, and p<0.05 was considered statistically significant. RESULTS: There was no significant difference in maternal age, gestational age, BMI, fasting glucose, and insulin levels between the groups. Both fasting and 120th-minute xenin-25 levels were significantly higher in the GDM group when compared to the control group (p<0.05). Both the fasting and 120th-minute serum xenin-25 levels were significantly higher in women with GDM compared to healthy pregnant women. CONCLUSIONS: High levels of xenin-25 were associated with gestational diabetes, and xenin-25 might be a potential marker for detecting GDM in the future.
- 1 October 2023
- Vol. 27 (20) , 9902-9907
Maternal serum xenin-25 levels in gestational diabetes mellitus
OBJECTIVE: Xenin-25 is a polypeptide having an insulinotropic effect via increasing the insulin-releasing action of glucose-dependent insulinotropic polypeptide (GIP) and promoting beta cell survival and proliferation. We aimed to assess serum xenin-25 levels in euglycemic pregnancies vs. pregnancies complicated with gestational diabetes mellitus (GDM). PATIENTS AND METHODS: Forty pregnancies complicated with GDM and 40 healthy pregnancies with gestational age between 24 and 28 weeks were included. Following eight hours of fasting, blood samples were drawn from the participants, and subsequently, 75 g of glucose was administered orally. Blood was drawn again 120 minutes after the glucose challenge. Serum xenin-25 levels were detected by ELISA. Statistical analysis was performed, and p<0.05 was considered statistically significant. RESULTS: There was no significant difference in maternal age, gestational age, BMI, fasting glucose, and insulin levels between the groups. Both fasting and 120th-minute xenin-25 levels were significantly higher in the GDM group when compared to the control group (p<0.05). Both the fasting and 120th-minute serum xenin-25 levels were significantly higher in women with GDM compared to healthy pregnant women. CONCLUSIONS: High levels of xenin-25 were associated with gestational diabetes, and xenin-25 might be a potential marker for detecting GDM in the future.
- Open Access
- 1 October 2023
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 7 (10) , 673-677
Evaluation of carotid artery Doppler measurements in late-onset fetal growth restriction: a cross-sectional study
Background/Aim: It has been reported that both the internal carotid artery (ICA) and the common carotid artery (CCA) are associated with hypoxia, also observed in late-onset fetal growth restriction (FGR). However, it has not yet been investigated whether these Doppler measurements differ in cases of late-onset FGR. This study evaluated the ICA and the CCA Doppler parameters in late-onset FGR fetuses and compared these measurements with those of healthy fetuses. Methods: This cross-sectional observational study comprised 75 singleton pregnancies diagnosed with late-onset FGR between the 32nd and 37th weeks of gestation, alongside 75 healthy fetuses paired 1:1 based on obstetric history and gestational age between June 2022 and May 2023. The Delphi consensus of 2016 was used for the definition of late-onset FGR. The exclusion criteria were congenital anomalies, presence of any additional disease, maternal body mass index over 35 kg/m2, abdominal scars hindering ultrasound visualization, use of medications such as antenatal steroids, sympathomimetics, and indomethacin that affect vascular function, drug use, smoking during pregnancy, concurrent preeclampsia, and multiple pregnancies. Upon the patients' admission to the hospital, their demographic characteristics were documented, and ultrasonographic examinations and Doppler measurements were subsequently performed. The Doppler velocimetry of the umbilical artery (UA) encompassed measurements of the systolic to diastolic ratio (S/D), pulsatility index (PI), and peak systolic velocity (PSV). The carotid artery Doppler velocimetry of the middle cerebral artery (MCA), ICA, and CCA encompassed measurements of the PI, resistance index (RI), and PSV. We assessed the diagnostic performance of Doppler measurements for late-onset FGR through receiver operating characteristic (ROC) analysis. Results: In the late-onset FGR group, the mean UA-SD was higher (2.7 [0.6] vs. 2.5 [0.5], P=0.006), and the mean UA-PI (0.8 [0.2] vs. 0.9 [0.2], P=0.011) and mean PSV (35.6 [8.2] vs. 41.1 [7.1], P<0.001) were lower compared to the control group. In the late-onset FGR group, carotid Doppler measurements were more pronounced than UA Doppler measurements. Moreover, ICA Doppler measurements exhibited superior diagnostic performance in predicting late-onset FGR compared to other Doppler measurements (Area under the curve [AUC]=0.777, P<0.001 for ICA-PI; AUC=0.751, P<0.001 for ICA-RI; AUC=0.749, P<0.001 for ICA-PSV). Conclusion: In fetuses with late-onset FGR, UA Doppler measurements showed minimal differences compared to healthy fetuses, but differences in carotid Doppler measurements, especially in the ICA, were more pronounced. Therefore, in the management of fetuses suspected of having late-onset FGR, a more detailed Doppler examination might be required.
- 1 October 2023
- Published by SelSistem in Journal of Surgery and Medicine
- Vol. 7 (10) , 673-677
Open AccessEvaluation of carotid artery Doppler measurements in late-onset fetal growth restriction: a cross-sectional study
Background/Aim: It has been reported that both the internal carotid artery (ICA) and the common carotid artery (CCA) are associated with hypoxia, also observed in late-onset fetal growth restriction (FGR). However, it has not yet been investigated whether these Doppler measurements differ in cases of late-onset FGR. This study evaluated the ICA and the CCA Doppler parameters in late-onset FGR fetuses and compared these measurements with those of healthy fetuses. Methods: This cross-sectional observational study comprised 75 singleton pregnancies diagnosed with late-onset FGR between the 32nd and 37th weeks of gestation, alongside 75 healthy fetuses paired 1:1 based on obstetric history and gestational age between June 2022 and May 2023. The Delphi consensus of 2016 was used for the definition of late-onset FGR. The exclusion criteria were congenital anomalies, presence of any additional disease, maternal body mass index over 35 kg/m2, abdominal scars hindering ultrasound visualization, use of medications such as antenatal steroids, sympathomimetics, and indomethacin that affect vascular function, drug use, smoking during pregnancy, concurrent preeclampsia, and multiple pregnancies. Upon the patients' admission to the hospital, their demographic characteristics were documented, and ultrasonographic examinations and Doppler measurements were subsequently performed. The Doppler velocimetry of the umbilical artery (UA) encompassed measurements of the systolic to diastolic ratio (S/D), pulsatility index (PI), and peak systolic velocity (PSV). The carotid artery Doppler velocimetry of the middle cerebral artery (MCA), ICA, and CCA encompassed measurements of the PI, resistance index (RI), and PSV. We assessed the diagnostic performance of Doppler measurements for late-onset FGR through receiver operating characteristic (ROC) analysis. Results: In the late-onset FGR group, the mean UA-SD was higher (2.7 [0.6] vs. 2.5 [0.5], P=0.006), and the mean UA-PI (0.8 [0.2] vs. 0.9 [0.2], P=0.011) and mean PSV (35.6 [8.2] vs. 41.1 [7.1], P<0.001) were lower compared to the control group. In the late-onset FGR group, carotid Doppler measurements were more pronounced than UA Doppler measurements. Moreover, ICA Doppler measurements exhibited superior diagnostic performance in predicting late-onset FGR compared to other Doppler measurements (Area under the curve [AUC]=0.777, P<0.001 for ICA-PI; AUC=0.751, P<0.001 for ICA-RI; AUC=0.749, P<0.001 for ICA-PSV). Conclusion: In fetuses with late-onset FGR, UA Doppler measurements showed minimal differences compared to healthy fetuses, but differences in carotid Doppler measurements, especially in the ICA, were more pronounced. Therefore, in the management of fetuses suspected of having late-onset FGR, a more detailed Doppler examination might be required.
- 16 April 2023
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 39 (3) , 134-137
Use of Virtual Touch Tissue Quantification Elastography Technique in Fetal Lung Maturation
This study is an analysis of fetal lung stiffness by virtual touch tissue quantification (VTTQ) elastography to predict fetal lung maturation. Evaluation of fetal lungs was first performed in B mode, and fetal lungs were analyzed at 3 different periods at third trimester in each pregnant woman, at 28 to 31, 32 to 36, and 37 to 41 weeks. Fetal lung elastography was performed at regions with the least acoustic shadow and far from ribs and heart. Each fetal lung assessment were done by taking mean lung stiffness obtained by measuring stiffness of both left and right fetal lungs. T test analysis showed no significant difference in fetal lung stiffness between male and female fetuses among 3 gestational periods. Analysis of variance was performed to evaluate fetal lung stiffness of the fetuses at 3 different gestational periods (28–31, 32–36, and 37–41 weeks). This analysis showed significant difference (P < 0.01). Duncan multiple comparison analysis did not show significant difference in fetal lung stiffness between 28 and 31 weeks and 32 and 36 weeks, whereas fetal lung stiffness of fetuses at 37 to 41 weeks were significantly greater (P < 0.01). This study is first step to analyze fetal lung maturation noninvasively using VTTQ elastography technique by measuring fetal lung stiffness.
- 16 April 2023
- Published by Wolters Kluwer Health in Ultrasound Quarterly
- Vol. 39 (3) , 134-137
Use of Virtual Touch Tissue Quantification Elastography Technique in Fetal Lung Maturation
This study is an analysis of fetal lung stiffness by virtual touch tissue quantification (VTTQ) elastography to predict fetal lung maturation. Evaluation of fetal lungs was first performed in B mode, and fetal lungs were analyzed at 3 different periods at third trimester in each pregnant woman, at 28 to 31, 32 to 36, and 37 to 41 weeks. Fetal lung elastography was performed at regions with the least acoustic shadow and far from ribs and heart. Each fetal lung assessment were done by taking mean lung stiffness obtained by measuring stiffness of both left and right fetal lungs. T test analysis showed no significant difference in fetal lung stiffness between male and female fetuses among 3 gestational periods. Analysis of variance was performed to evaluate fetal lung stiffness of the fetuses at 3 different gestational periods (28–31, 32–36, and 37–41 weeks). This analysis showed significant difference (P < 0.01). Duncan multiple comparison analysis did not show significant difference in fetal lung stiffness between 28 and 31 weeks and 32 and 36 weeks, whereas fetal lung stiffness of fetuses at 37 to 41 weeks were significantly greater (P < 0.01). This study is first step to analyze fetal lung maturation noninvasively using VTTQ elastography technique by measuring fetal lung stiffness.
- Open Access
- 30 January 2023
- Published by Wiley
Effect of magnesium sulfate seizure prophylaxis on fetal myocardial performance index in severe preeclampsia and eclampsia
Objective: This study aimed to investigate the effect of magnesium sulfate treatment on fetal cardiac function during seizure prophylaxis of pregnant women diagnosed with severe preeclampsia and eclampsia. Fetal cardiac function was evaluated with the modified myocardial performance index (mod-MPI) before and after prophylaxis. Methods: A total of 50 pregnant women diagnosed with severe preeclampsia or eclampsia were involved. The characteristics of the participants, medical and obstetric history, ultrasound and laboratory findings were recorded. Fetal mod-MPI was obtained before and after magnesium treatment. Data were analyzed with appropriate statistical tests and p < 0.05 was considered to indicate statistical significance . Results: The mean maternal and gestational ages of pregnant women were 31.7 ± 5.9 and 32.4 ± 4.5. Mean mod-MPI before and after prophylaxis were 0.41 ± 0.18 and 0.49 ± 0.09, respectively (pConclusion: There was a significant increase in fetal mod-MPI after magnesium prophylaxis was given to severe preeclampctic/eclamptic women. The higher the mod-MPI, the worse the fetal cardiac function. This might have been the result of magnesium leading to an increased isovolumetric relaxation time. Key words: Preeclampsia, magnesium sulfate, myocardial performance index, eclampsia, fetus
- 30 January 2023
- Published by Wiley
Open AccessEffect of magnesium sulfate seizure prophylaxis on fetal myocardial performance index in severe preeclampsia and eclampsia
Objective: This study aimed to investigate the effect of magnesium sulfate treatment on fetal cardiac function during seizure prophylaxis of pregnant women diagnosed with severe preeclampsia and eclampsia. Fetal cardiac function was evaluated with the modified myocardial performance index (mod-MPI) before and after prophylaxis. Methods: A total of 50 pregnant women diagnosed with severe preeclampsia or eclampsia were involved. The characteristics of the participants, medical and obstetric history, ultrasound and laboratory findings were recorded. Fetal mod-MPI was obtained before and after magnesium treatment. Data were analyzed with appropriate statistical tests and p < 0.05 was considered to indicate statistical significance . Results: The mean maternal and gestational ages of pregnant women were 31.7 ± 5.9 and 32.4 ± 4.5. Mean mod-MPI before and after prophylaxis were 0.41 ± 0.18 and 0.49 ± 0.09, respectively (pConclusion: There was a significant increase in fetal mod-MPI after magnesium prophylaxis was given to severe preeclampctic/eclamptic women. The higher the mod-MPI, the worse the fetal cardiac function. This might have been the result of magnesium leading to an increased isovolumetric relaxation time. Key words: Preeclampsia, magnesium sulfate, myocardial performance index, eclampsia, fetus